190142-10-0Relevant academic research and scientific papers
Azotides as Modular Peptide-Based Ligands for Asymmetric Lewis Acid Catalysis
Jacobsen, Christian Borch,Nielsen, Daniel Steen,Meldal, Morten,Diness, Frederik
, p. 6940 - 6945 (2019/06/10)
Synthesis of azotides and evaluation of these as ligands for enantioselective Lewis acid catalysis is reported. The ligands were readily prepared from the chiral pool of amino acids and perform well in the cobalt(II)-catalyzed formation of asymmetric hete
Protease inhibitors
-
, (2008/06/13)
The present invention provides compounds of formula (I) which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia or malignancy; and metabolic bone disease therewith.
Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily
-
, (2008/06/13)
The present invention relates to compounds and pharmaceutical compositions which inhibit proteases, such as cysteine proteases. In particular, the present invention relates to compounds and pharmaceutical compositions which inhibit cysteine proteases of the papain superfamily. The compounds and pharmaceutical compositions of the present invention are useful for treating diseases, particularly parasitic diseases, which are mediated by such proteases. In particular, the present invention relates to a method of treating malaria by inhibiting the cysteine protease falcipain.
Design and synthesis of diaminopyrrolidinone inhibitors of human osteoclast cathepsin K
Duffy, Kevin J.,Ridgers, Lance H.,Desjarlais, Renee L.,Tomaszek, Thaddeus A.,Bossard, Mary J.,Thompson, Scott K.,Keenan, Richard M.,Veber, Daniel F.
, p. 1907 - 1910 (2007/10/03)
The structure-based design and synthesis of lactam-constrained azapeptide inhibitors of human cathepsin K are described. Enhanced stability to proteolytic cleavage over acyclic analogues is discussed.
PROTEASE INHIBITORS
-
, (2008/06/13)
Disclosed herein is a compound of the formula STR1 known as 2-[N-(N-benzyloxycarbonyl-L-leucinyl)]-2'-[N'-[4-(N,N-dimethylaminomethyl) benzyloxy]carbonyl-L-leucinyl]carbohydrazide; and pharmaceutically acceptable salts, hydrates and solvates thereof.
